Abstract
Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Neutralizing / administration & dosage
-
Antibodies, Neutralizing / immunology*
-
Cell Line
-
Child
-
Child, Preschool
-
Cross Reactions / immunology
-
Dogs
-
Dose-Response Relationship, Immunologic
-
Hemagglutination Inhibition Tests
-
Humans
-
Immunoglobulins, Intravenous / administration & dosage
-
Immunoglobulins, Intravenous / immunology*
-
Infant
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza, Human / epidemiology
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control
-
Influenza, Human / virology*
-
Mucocutaneous Lymph Node Syndrome / immunology
-
Neutralization Tests
-
Pandemics
Substances
-
Antibodies, Neutralizing
-
Immunoglobulins, Intravenous